NCT03375320 2026-03-18Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNational Cancer Institute (NCI)Phase 3 Active not recruiting298 enrolled 14 charts 1 FDA
NCT03690388 2025-09-25A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyExelixisPhase 3 Active not recruiting187 enrolled 13 charts 1 FDA